Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with Fludarabine and Rituximab in Relapsed/Refractory CLL/SLL
NCT01173679Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2010
- Primary completion
- Jan 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Massachusetts General Hospital. Started Jul 2010; status: terminated.
02
Drugs
dasatinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01173679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01173679.